



US008475832B2

(12) **United States Patent**
Myers et al.

(10) **Patent No.:** **US 8,475,832 B2**
(45) **Date of Patent:** **Jul. 2, 2013**

(54) **SUBLINGUAL AND BUCCAL FILM**
COMPOSITIONS

(75) Inventors: **Garry L. Myers**, Kingsport, TN (US);
Samuel D. Hilbert, Jonesboro, TN (US);
Bill J. Boone, Johnson City, TN (US); **B.**
Arlie Bogue, New Carlisle, IN (US);
Pradeep Sanghvi, Schererville, IN (US);
Madhusudan Hariharan, Munster, IN
(US)

(73) Assignee: **RB Pharmaceuticals Limited**, Slough
(GB)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 231 days.

(21) Appl. No.: **12/537,571**

(22) Filed: **Aug. 7, 2009**

(65) **Prior Publication Data**

US 2011/0033541 A1 Feb. 10, 2011

(51) **Int. Cl.**
A61F 13/00 (2006.01)
A61K 9/14 (2006.01)
A61K 31/44 (2006.01)

(52) **U.S. Cl.**
USPC **424/435**; 424/422; 424/434; 424/484;
514/282

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

307,537 A 11/1884 Foulks
688,446 A 12/1901 Stempel
2,980,554 A 4/1961 Gentile et al.
3,007,848 A 11/1961 Stroop
3,249,109 A 5/1966 Maeth et al.
3,444,858 A 5/1969 Russell
3,536,809 A 10/1970 Applezweig
3,551,556 A 12/1970 Kliment et al.
3,598,122 A 8/1971 Zaffaroni
3,632,740 A 1/1972 Robinson et al.
3,640,741 A 2/1972 Etes
3,641,237 A 2/1972 Gould et al.
3,731,683 A 5/1973 Zaffaroni
3,753,732 A 8/1973 Boroshok
3,814,095 A 6/1974 Lubens
3,892,905 A 7/1975 Albert
3,911,099 A 10/1975 DeFoney et al.
3,972,995 A 8/1976 Tsuk et al.
3,996,934 A 12/1976 Zaffaroni
4,029,757 A 6/1977 Mlodozieniec et al.
4,029,758 A 6/1977 Mlodozieniec et al.
4,031,200 A 6/1977 Reif
4,123,592 A 10/1978 Rainer et al.
4,128,445 A 12/1978 Sturzenegger et al.
4,136,145 A 1/1979 Fuchs et al.
4,136,162 A 1/1979 Fuchs et al.
4,139,627 A 2/1979 Lane et al.

4,292,299 A 9/1981 Suzuki et al.
4,294,820 A 10/1981 Keith et al.
4,302,465 A 11/1981 Ekenstam et al.
4,307,075 A 12/1981 Martin
4,325,855 A 4/1982 Dickmann et al.
4,373,036 A 2/1983 Chang et al.
4,406,708 A 9/1983 Hesselgren
4,432,975 A 2/1984 Libby
4,438,258 A 3/1984 Graham
4,460,562 A 7/1984 Keith et al.
4,466,973 A 8/1984 Rennie
4,503,070 A 3/1985 Eby, III
4,515,162 A 5/1985 Yamamoto et al.
4,517,173 A 5/1985 Kizawa et al.
4,529,601 A 7/1985 Broberg et al.
4,529,748 A 7/1985 Wienecke
4,562,020 A 12/1985 Hijjiya et al.
4,569,837 A 2/1986 Suzuki et al.
4,582,835 A 4/1986 Lewis et al.
4,593,053 A 6/1986 Jevne et al.
4,608,249 A 8/1986 Otsuka et al.
4,615,697 A 10/1986 Robinson
4,623,394 A 11/1986 Nakamura et al.
4,631,837 A 12/1986 Magoon
4,652,060 A 3/1987 Miyake
4,659,714 A 4/1987 Watt-Smith
4,675,009 A 6/1987 Hymes et al.
4,695,465 A 9/1987 Kigasawa et al.
4,704,119 A 11/1987 Shaw et al.
4,713,239 A 12/1987 Babaian et al.
4,713,243 A 12/1987 Schiraldi et al.
4,722,761 A 2/1988 Cartmell et al.
4,740,365 A 4/1988 Yukimatsu et al.
4,748,022 A 5/1988 Busciglio
4,765,983 A 8/1988 Takayanagi et al.
4,772,470 A 9/1988 Inoue et al.
4,777,046 A 10/1988 Iwakura et al.
4,789,667 A 12/1988 Makino et al.
4,849,246 A 7/1989 Schmidt
4,860,754 A 8/1989 Sharik et al.
RE33,093 E 10/1989 Schiraldi et al.
4,876,092 A 10/1989 Mizobuchi et al.
4,876,970 A 10/1989 Bolduc
4,888,354 A 12/1989 Chang et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU 741362 B2 7/1998
DE 2432925 B2 1/1976

(Continued)

OTHER PUBLICATIONS

Lazaridou et al., "Thermophysical properties of chitosan, chitosan-starch and chitosan-pullulan films near the glass transition," Carbohydrate Polymers 48: 179-190 (2002).

(Continued)

Primary Examiner — Janet Epps-Smith
(74) Attorney, Agent, or Firm — Hoffmann & Baron, LLP

(57) **ABSTRACT**

The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.

U.S. PATENT DOCUMENTS

4,894,232 A 1/1990 Reül et al.
 4,900,552 A 2/1990 Sanvordeker et al.
 4,900,554 A 2/1990 Yanagibashi et al.
 4,900,556 A 2/1990 Wheatley et al.
 4,910,247 A 3/1990 Haldar et al.
 4,915,950 A 4/1990 Miranda et al.
 4,925,670 A 5/1990 Schmidt
 4,927,634 A 5/1990 Sorrentino et al.
 4,927,636 A 5/1990 Hijjiya et al.
 4,937,078 A 6/1990 Mezei et al.
 4,940,587 A 7/1990 Jenkins et al.
 4,948,580 A 8/1990 Browning
 4,958,580 A 9/1990 Asaba et al.
 4,978,531 A 12/1990 Yamazaki et al.
 4,981,693 A 1/1991 Higashi et al.
 4,981,875 A 1/1991 Leusner et al.
 5,023,082 A 6/1991 Friedman et al.
 5,024,701 A 6/1991 Desmarais
 5,028,632 A 7/1991 Fuisz
 5,045,445 A 9/1991 Schultz
 5,047,244 A 9/1991 Sanvordeker et al.
 5,064,717 A 11/1991 Suzuki et al.
 5,089,307 A 2/1992 Ninomiya et al.
 5,118,508 A 6/1992 Kikuchi et al.
 5,158,825 A 10/1992 Altwirth
 5,166,233 A 11/1992 Kuroya et al.
 5,186,938 A 2/1993 Sablotsky et al.
 5,229,164 A 7/1993 Pins et al.
 5,234,957 A 8/1993 Mantelle
 5,271,940 A 12/1993 Cleary et al.
 5,272,191 A 12/1993 Ibrahim et al.
 5,346,701 A 9/1994 Heiber et al.
 5,393,528 A 2/1995 Staab
 5,411,945 A 5/1995 Ozaki et al.
 5,413,792 A 5/1995 Ninomiya et al.
 5,433,960 A 7/1995 Meyers
 5,455,043 A 10/1995 Fischel-Ghodsian
 5,462,749 A 10/1995 Rencher
 5,472,704 A 12/1995 Santus et al.
 5,518,902 A 5/1996 Ozaki et al.
 5,567,431 A 10/1996 Vert et al.
 5,605,696 A 2/1997 Eury et al.
 5,620,757 A 4/1997 Ninomiya et al.
 5,629,003 A 5/1997 Horstmann et al.
 5,681,873 A 10/1997 Norton et al.
 5,700,478 A 12/1997 Biegajski et al.
 5,700,479 A 12/1997 Lundgren
 5,766,332 A 6/1998 Graves et al.
 5,766,620 A 6/1998 Heiber et al.
 5,766,839 A 6/1998 Johnson et al.
 5,800,832 A 9/1998 Tapolsky et al.
 5,806,284 A 9/1998 Gifford
 5,891,461 A 4/1999 Jona et al.
 5,900,247 A 5/1999 Rault et al.
 5,948,430 A 9/1999 Zerbe et al.
 6,072,100 A 6/2000 Mooney et al.
 6,103,266 A 8/2000 Tapolsky et al.
 6,153,210 A 11/2000 Roberts et al.
 6,159,498 A 12/2000 Tapolsky et al.
 6,177,096 B1 1/2001 Zerbe et al.
 6,231,957 B1 5/2001 Zerbe et al.
 6,264,981 B1 7/2001 Zhang et al.
 6,284,264 B1 9/2001 Zerbe et al.
 6,375,963 B1 4/2002 Repka et al.
 6,503,532 B1 1/2003 Murty et al.
 6,667,060 B1 12/2003 Vandecruys et al.
 6,800,329 B2 10/2004 Horstmann et al.
 6,824,829 B2 11/2004 Berry et al.
 7,005,142 B2 2/2006 Leon
 7,579,019 B2 8/2009 Tapolsky et al.
 2001/0006677 A1 7/2001 McGinity et al.
 2001/0022964 A1 9/2001 Leung et al.
 2001/0046511 A1 11/2001 Zerbe et al.
 2003/0069263 A1 4/2003 Breder et al.
 2003/0107149 A1 6/2003 Yang et al.
 2003/0124176 A1 7/2003 Hsu et al.

2005/0048102 A1 3/2005 Tapolsky et al.
 2005/0118217 A1 6/2005 Barnhart et al.
 2005/0147658 A1 7/2005 Tapolsky et al.
 2005/0192309 A1 9/2005 Palermo et al.
 2006/0210610 A1 9/2006 Davidson et al.
 2006/0281775 A1 12/2006 Kelly, II et al.
 2007/0087036 A1 4/2007 Durschlag et al.
 2007/0148097 A1 6/2007 Finn et al.
 2008/0254105 A1 10/2008 Tapolsky et al.
 2010/0015128 A1 1/2010 Lee et al.
 2010/0087470 A1* 4/2010 Oksche et al. 514/279
 2011/0189259 A1 8/2011 Vasisht et al.
 2011/0262522 A1 10/2011 Finn et al.

FOREIGN PATENT DOCUMENTS

DE 2449865 B2 4/1976
 DE 3630603 C2 3/1988
 EP 0219762 B1 12/1990
 EP 0259749 B1 8/1991
 EP 0200508 B1 10/1991
 EP 0241178 B1 1/1992
 EP 0273069 B1 10/1992
 EP 0250187 B1 9/1993
 EP 0452446 B1 12/1993
 EP 0381194 B1 8/1994
 EP 0440462 B1 12/1994
 EP 0514691 B1 3/1996
 EP 0598606 B1 6/1999
 EP 0949925 B1 10/1999
 EP 1110546 A1 6/2001
 EP 1897543 A1 3/2008
 GB 2447016 A 9/2008
 JP 62126950 6/1987
 JP 02265444 10/1990
 JP 05147140 6/1993
 JP 07322812 12/1995
 JP 2001279100 10/2001
 WO 9105540 A1 5/1991
 WO 9215289 A1 9/1992
 WO 9505416 A2 2/1995
 WO 9518046 A1 7/1995
 WO 9817251 4/1998
 WO 9955312 11/1999
 WO 0018365 A2 4/2000
 WO 0042992 A2 7/2000
 WO 0170194 A1 9/2001
 WO 0191721 A2 12/2001
 WO 03/030882 A1 4/2003
 WO 03030883 A1 4/2003
 WO 2007070632 A2 6/2007
 WO 2008011194 A2 1/2008
 WO WO 2008025791 A1* 3/2008

OTHER PUBLICATIONS

Repka et al., "Bioadhesive Properties of hydroxypropylcellulose topical films produced by hot melt extrusion," Journal of Controlled Release, 70: 341-351 (2001).
 Repka et al., "Influence of Vitamin E TPGS on the properties of hydrophilic films produced by hot melt extrusion", International Journal of Pharmaceutics 202: 63-70 (2000).
 Peh and Wong, Polymeric Films as Vehicle for Buccal Delivery: Swelling, Mechanical, and Bioadhesive Properties, J Pharm Pharmaceut Sci (www.ualberta.ca/~csps) 2 (2):53-61, 1999.
 Bodmeier. Pharmaceutical Research, vol. 6, No. 8, 1989.
 "Suboxone Sublingualtableten" In: Verlag Rote Liste Service GmbH: "Rote Liste 2008" 2008, Verlag Rote Liste Service GmbH, Frankfurt/Main, XP002624986, p. 39018, the whole document.
 Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the

Written Opinion of the International Searching Authority for International Application No. PCT/US2010/044488 dated Apr. 11, 2011.

Abeer M. Al-Ghananeem et al., "Effect of pH on Sublingual Absorption of Oxycodone Hydrochloride." AAPS PharmSciTech 2006; 7(1) Article 23 (<http://www.aapspharmscitech.org>).

Mahmood et al., "A limited sampling method for the estimation of AUC and C_{max} of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product." BrJ Clin Pharmacol 1998; 45: pp. 241-246.

* cited by examiner

1

SUBLINGUAL AND BUCCAL FILM COMPOSITIONS

FIELD OF THE INVENTION

The present invention relates to compositions, methods of manufacture, products and methods of use relating to films containing therapeutic actives. The invention more particularly relates to self-supporting film dosage forms which provide a therapeutically effective dosage, essentially matching that of currently-marketed tablets containing the same active. Such compositions are particularly useful for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.

BACKGROUND OF THE RELATED TECHNOLOGY

Oral administration of two therapeutic actives in a single dosage form can be complex if the intention is to have one active absorbed into the body and the other active remain substantially unabsorbed. For example, one active may be relatively soluble in the mouth at one pH, and the other active may be relatively insoluble at the same pH. Moreover, the absorption kinetics of each therapeutic agent may be substantially different due to differing absorption of the charged and uncharged species. These factors represent some of the challenges in appropriately co-administering therapeutic agents.

Co-administration of therapeutic agents has many applications. Among such areas of treatment include treating individuals who suffer from narcotic dependence. Such individuals have a tendency to suffer from serious physical dependence on the narcotic, resulting in potentially dangerous withdrawal effects when the narcotic is not administered to the individual. In order to help individuals addicted to narcotics, it is known to provide a reduced level of a drug, which provides an effect of satisfying the body's urge for the narcotic, but does not provide the "high" that is provided by the misuse of the narcotic. The drug provided may be an agonist or a partial agonist, which provides a reduced sensation and may help lower dependence on the drug. However, even though these drugs provide only a low level of euphoric effect, they are capable of being abused by the individuals parenterally. In such cases, it is desirable to provide a combination of the drug with a second drug, which may decrease the likelihood of diversion and abuse of the first drug. For example, it is known to provide a dosage of an antagonist in combination with the agonist or partial agonist. The narcotic antagonist binds to a receptor in the brain to block the receptor, thus reducing the effect of the agonist.

One such combination of drugs has been marketed under the trade name Suboxone® as an orally ingestible tablet. However, such combinations in tablet form have the potential for abuse. In some instances, the patient who has been provided the drug may store the tablet in his mouth without swallowing the tablet, then later extract the agonist from the tablet and inject the drug into an individual's body. Although certain antagonists (such as highly water-soluble antagonists) may be used to help reduce the ability to separate the agonist, the potential for abuse still exists. It is desired to provide a dosage that cannot be easily removed from the mouth once it has been administered.

There is currently a need for an orally dissolvable film

2

the mouth, rendering it difficult to remove once placed in the mouth, thereby making abuse of the agonist difficult.

SUMMARY OF THE INVENTION

In one embodiment of the present invention, there is provided a film dosage composition including: a polymeric carrier matrix; a therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof; and a buffer in an amount to provide a pH of the composition of a value sufficient to optimize absorption of the buprenorphine.

In another embodiment of the present invention, there is provided a film dosage composition including: a polymeric carrier matrix; a therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof; and a buffer in an amount sufficient to inhibit the absorption of the naloxone when administered orally.

In still other embodiments, there may be provided a film dosage composition including: a polymeric carrier matrix; a therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof; and a buffering system; where the buffering system includes a buffer capacity sufficient to maintain the ionization of naloxone during the time which the composition is in the oral cavity of a user.

In another embodiment of the invention, there is provided a method of treating narcotic dependence of a user, including the steps of: providing a composition including: a polymeric carrier matrix; a therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof, and a buffer in an amount to provide a pH of the composition of a value sufficient to optimize absorption of the buprenorphine; and administering the composition to the oral cavity of a user.

In still another embodiment of the invention, there is provided a process of forming a film dosage composition including the steps of: casting a film-forming composition, the film-forming composition including: a polymeric carrier matrix; a therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof, and a buffer in an amount to provide a pH of the composition of a value sufficient to optimize absorption of the buprenorphine and drying the film-forming composition to form a self-supporting film dosage composition.

In another embodiment, there is provided a film dosage composition including a therapeutically sufficient amount of buprenorphine or a pharmaceutically acceptable salt thereof and a therapeutically sufficient amount of naloxone or a pharmaceutically acceptable salt thereof, the film dosage composition having a bioequivalent release profile as compared to a Suboxone® tablet containing about 2 times the amount of buprenorphine or a pharmaceutically acceptable salt thereof.

Still other embodiments of the present invention provide an orally dissolving film formulation including buprenorphine and naloxone, where the formulation provides an in-vivo

plasma profile having a C_{max} of between about 41.04 pg/ml to about 323.75 pg/ml for naloxone.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Definitions

As used herein, the term C_{max} refers to the mean maximum plasma concentration after administration of the composition to a human subject. As also used herein, the term AUC refers to the mean area under the plasma concentration-time curve value after administration of the compositions formed herein. As will be set forth in more detail below, the term “optimizing the absorption” does not refer to reaching the maximum absorption of the composition, and rather refers to reaching the optimum level of absorption at a pH of about 2 to about 4. The “optimum” absorption may be, for example, a level that provides a bioequivalent absorption as administration of the currently available Suboxone® tablet. An “optimum” C_{max} of buprenorphine is about 0.67 to about 5.36 mg/ml at dosages of from 2-16 mg buprenorphine at a given pH. Similarly, an “optimum” AUC of buprenorphine may be about 7.43 to about 59.46 hr*ng/ml at dosages of from 2-16 mg buprenorphine at a given pH. As will be described in more detail below, it has been surprisingly discovered that the absorption of one particular agonist, buprenorphine, can provide an optimum absorption at a pH of about 2-4 as well as about 5.5-6.5. Thus, one may “optimize” the absorption of buprenorphine by providing a pH of about 2-4 or about 5.5-6.5.

“Maximizing the absorption” refers to the maximum in vivo absorption values achieved at a pH of about 4 to about 9.

The term “local pH” refers to the pH of the region of the carrier matrix immediately surrounding the active agent as the matrix hydrates and/or dissolves, for example, in the mouth of the user.

By “inhibiting” the absorption of an active, it is meant achieving as complete an ionization state of the active as possible, such that little to none of the active is measurably absorbable. For example, at a pH of 3-3.5, the C_{max} of an active such as naloxone for dosage of 0.5 mg to 4.0 mg ranges from 32.5 to 260 pg/ml, and an AUC of naloxone for dosage of 0.5 mg to 4.0 mg ranges from 90.55 to 724.4 hr*pg/ml. It is understood that at a pH lower than 3.0, further ionization would be expected and thus result in lower absorption.

The term “bioequivalent” means obtaining 80% to 125% of the C_{max} and AUC values for a given active in a different product. For example, assuming C_{max} and AUC values of buprenorphine for a commercially-available Suboxone® tablet (containing 2 mg buprenorphine and 0.5 mg naloxone) are 0.780 ng/ml and 6.789 hr*ng/ml, respectively, a bioequivalent product would have a C_{max} of buprenorphine in the range of 0.624-0.975 ng/ml, and an AUC value of buprenorphine of 5.431-8.486 hr*ng/ml.

It will be understood that the term “film” includes thin films and sheets, in any shape, including rectangular, square, or other desired shape. The films described herein may be any desired thickness and size such that it may be placed into the oral cavity of the user. For example, the films may have a relatively thin thickness of from about 0.1 to about 10 mils, or they may have a somewhat thicker thickness of from about 10 to about 30 mils. For some films, the thickness may be even larger, i.e., greater than about 30 mils. Films may be in a

Oral dissolving films generally fall into three main classes: fast dissolving, moderate dissolving and slow dissolving. Fast dissolving films generally dissolve in about 1 second to about 30 seconds in the mouth. Moderate dissolving films generally dissolve in about 1 to about 30 minutes in the mouth, and slow dissolving films generally dissolve in more than 30 minutes in the mouth. Fast dissolving films may consist of low molecular weight hydrophilic polymers (i.e., polymers having a molecular weight between about 1,000 to 9,000, or polymers having a molecular weight up to 200,000). In contrast, slow dissolving films generally have high molecular weight polymers (i.e., having a molecular weight in the millions).

Moderate dissolving films tend to fall in between the fast and slow dissolving films. Moderate dissolving films dissolve rather quickly, but also have a good level of mucoadhesion. Moderate dissolving films are also flexible, quickly wetttable, and are typically non-irritating to the user. For the instant invention, it is preferable to use films that fall between the categories of fast dissolving and moderate dissolving. Such moderate dissolving films provide a quick enough dissolution rate, most desirably between about 1 minute and about 20 minutes, while providing an acceptable mucoadhesion level such that the film is not easily removable once it is placed in the oral cavity of the user.

Inventive films described herein may include one or more agonists or partial agonists used for the treatment of drug addiction. As used herein, the term “agonist” refers to a chemical substance that is capable of providing a physiological response or activity in the body of the user. The films described herein may further include one or more antagonists. As used herein, the term “antagonist” refers to any chemical substance that acts within the body of the user to reduce the physiological activity of another chemical substance. In some embodiments, an antagonist used herein may act to reduce and/or block the physiological activity of the agonist. The actives may be water-soluble, or they may be water-insoluble. As used herein, the term “water-soluble” refers to substances that are at least partially dissolvable in a solvent, including but not limited to water. The term “water-soluble” does not necessarily mean that the substance is 100% dissolvable in the solvent. The term “water-insoluble” refers to substances that are not dissolvable in a solvent, including but not limited to water. Solvents may include water, or alternatively may include other polar solvents by themselves or in combination with water.

Inventive Films

The present invention relates to methods of treating narcotic dependence in an individual. More desirably, the invention relates to the treatment of opioid dependence in an individual, while using a formulation and delivery that hinders misuse of the narcotic. Currently, treatment of opioid dependence is aided by administration of Suboxone®, which is an orally dissolvable tablet. This tablet which provides a combination of buprenorphine (an opioid agonist) and naloxone (an opioid antagonist). Therefore, the present invention provides a method of treating narcotic dependence by providing an orally dissolvable film dosage, which provides a bioequivalent effect to Suboxone®. The film dosage preferably provides buccal adhesion while it is in the user’s mouth, rendering it difficult to remove after placement.

The film dosage composition preferably includes a polymeric carrier matrix. Any desired polymeric carrier matrix may be used, provided that it is orally dissolvable. Desirably, the dosage should have enough bioadhesion to not be easily removed and it should form a gel like structure when admin-

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.